Torsades de Pointes: How a Long QT Twists Into Cardiac Arrest

What It Is and Why It Matters

Torsades de Pointes (TdP) is a distinctive form of polymorphic ventricular tachycardia that occurs only in the setting of abnormal ventricular repolarization, marked by a prolonged QT interval. Rates typically run 200–250 bpm. It matters because it is a common final pathway for drug-induced arrhythmia and inherited channelopathies — and because it is one of the few arrhythmias where the trigger is often iatrogenic and preventable.

The underlying long QT can be:

• Congenital — long QT syndrome (LQTS), most often KCNQ1 (LQT1), KCNH2/hERG (LQT2), or SCN5A (LQT3).
• Acquired — the far more common form, driven by QT-prolonging drugs, hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, or hypothyroidism.

Because dozens of everyday drugs prolong QT — antiarrhythmics (sotalol, dofetilide, quinidine), macrolides and fluoroquinolones, antipsychotics (haloperidol), methadone, and antiemetics (ondansetron, droperidol) — every clinician who prescribes must recognize the TdP risk. Combined QT-prolongers, especially with an electrolyte deficit, are the highest-risk scenario.

The Mechanism, Step by Step

TdP is a two-hit process: a trigger (an afterdepolarization) firing onto a vulnerable substrate (dispersed, prolonged repolarization).

• Step 1 — Repolarization is delayed. The main outward current ending the action potential is the rapid delayed-rectifier potassium current IKr, carried by the hERG (KCNH2) channel. Blocking IKr — by drugs or a channel mutation — prolongs the action potential and the QT interval.
• Step 2 — Reactivation of calcium channels. With repolarization stretched out, L-type calcium channels recover from inactivation and reopen during the plateau, producing an early afterdepolarization (EAD) — a secondary upstroke before the cell has fully reset.
• Step 3 — Triggered beat. If an EAD reaches threshold, it fires a premature ventricular complex, classically after a pause (the short–long–short sequence).
• Step 4 — Reentry. Because repolarization is heterogeneous across the myocardial wall (transmural dispersion, driven by M-cells), the triggered beat encounters tissue in mixed refractory states and sets up a rotating reentrant circuit — the twisting waveform.

Bradycardia and low potassium amplify this cascade, which is why pause-dependent TdP is characteristic.

Clinical Presentation and Classic Signs

Patients present along a spectrum from asymptomatic ectopy to arrest. Because TdP episodes are usually self-terminating lasting seconds, the hallmark clinical event is recurrent syncope or near-syncope, sometimes mistaken for seizures (convulsive syncope from cerebral hypoperfusion).

• Palpitations and lightheadedness immediately before collapse.
• Sudden loss of consciousness without warning, often precipitated by a trigger — adrenergic surge (exercise, fright, loud noise) in LQT1/LQT2, or rest/sleep in LQT3.
• Sudden cardiac death if an episode degenerates into ventricular fibrillation.

The classic bedside/monitor sign is the arrhythmia itself: polymorphic VT in which the QRS peaks appear to spiral around the isoelectric line, with amplitude waxing and waning over a few beats. In inherited LQTS, look for a family history of unexplained sudden death, drowning, or SIDS. A history of a new QT-prolonging drug, diuretic-induced hypokalemia, or an eating disorder (electrolyte loss) is a major red flag that should prompt an ECG before symptoms escalate.

Diagnosis — ECG, Cutoffs, and Workup

Diagnosis is electrocardiographic, made by capturing the arrhythmia on a rhythm strip and documenting the substrate on the resting ECG.

• During the event: polymorphic VT with the characteristic sinusoidal 'twisting' of QRS amplitude and axis around the baseline — the defining sign of TdP versus generic polymorphic VT.
• Between events: a prolonged QT interval. Corrected QT (QTc) is calculated with Bazett's formula (QTc = QT ÷ √RR). Normal upper limits are roughly ≤ 450 ms in men and ≤ 460 ms in women; a QTc > 500 ms markedly raises TdP risk, and each 10 ms above baseline incrementally increases risk.
• Look for abnormal T-U waves, T-wave alternans, and the short–long–short initiating sequence.

Supporting workup: check potassium, magnesium, and calcium (hypokalemia, hypomagnesemia, hypocalcemia all prolong QT); review the medication list for QT offenders and CYP inhibitors that raise their levels; and screen TSH. For suspected congenital LQTS, the Schwartz score stratifies probability and prompts genetic testing (KCNQ1, KCNH2, SCN5A). Manual QT measurement in the lead with the longest interval (often II or V5–V6) is preferred over automated readings.

Management at the Mechanism Level

Treatment targets the electrophysiologic triggers directly.

• IV magnesium sulfate (2 g bolus) — the first-line drug, given even when serum magnesium is normal. Magnesium suppresses the L-type-calcium-driven EADs that trigger TdP; it stabilizes without necessarily shortening the QT.
• Correct electrolytes — aggressively repletewto potassium to a high-normal target (~4.5–5.0 mmol/L); more IKr channels conduct at higher extracellular K⁺, hastening repolarization.
• Increase heart rate / shorten the QT — since TdP is pause-dependent, raising the rate to ~90–110 bpm shortens repolarization and abolishes pauses. Achieve this with isoproterenol (in acquired TdP, unless congenital LQTS or ischemia) or temporary transvenous overdrive pacing.
• Stop the offending drug and remove every QT-prolonging agent.
• Defibrillation for sustained TdP degenerating to VF or hemodynamic collapse.

Critically, avoid Class Ia and Class III antiarrhythmics (they further block IKr and prolong QT). For inherited LQTS, long-term therapy is beta-blockers (nadolol, propranolol) and an ICD in high-risk survivors.

Mimics, Pitfalls, and Significance

The key discriminator is the QT interval: polymorphic VT with a normal baseline QT is not TdP — it usually reflects acute ischemia and warrants revascularization plus amiodarone, not magnesium or isoproterenol. Misapplying isoproterenol to ischemic polymorphic VT can be harmful.

• Do-not-miss pitfall: giving isoproterenol/rate acceleration to a patient with congenital LQTS (especially catecholamine-triggered LQT1/LQT2) can worsen the arrhythmia — beta-blockade, not sympathomimetics, is correct there.
• Drug-drug traps: a CYP3A4 inhibitor (e.g., a macrolide or azole) raising the level of a QT-prolonging substrate can precipitate TdP even when neither drug alone would.
• Distinguish from: monomorphic VT (uniform QRS, scar-based), ventricular fibrillation (no organized complexes), and artifact.

Significance: TdP is the classic paradigm linking molecular channelopathy to sudden death. It is also the reason drug regulators mandate 'thorough QT' studies — hERG blockade has withdrawn drugs (terfenadine, cisapride, astemizole) from the market. Recognizing a lengthening QTc is often the only warning before the twist begins.

Torsades de Pointes vs. other wide-complex tachycardias

Feature	Torsades de Pointes	Monomorphic VT	Ventricular Fibrillation
QRS morphology	Polymorphic, amplitude twists around baseline	Uniform, single stable morphology	Chaotic, no discernible complexes
Baseline QT	Prolonged (QTc often > 500 ms)	Usually normal	N/A
Typical substrate	Repolarization delay + EAD trigger	Scar/reentry (prior MI, cardiomyopathy)	Ischemia, degenerated VT
Onset pattern	Often 'short-long-short' cycle (pause-dependent)	Sustained, regular	Sudden, disorganized
First-line drug	IV magnesium sulfate	Amiodarone / procainamide	Immediate defibrillation
Class III / QT drugs	Contraindicated (worsen QT)	May be used	Avoid QT-prolongers